Eterna Therapeutics Net Worth
Eterna Therapeutics Net Worth Breakdown | ERNA |
Eterna Therapeutics Net Worth Analysis
Eterna Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eterna Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eterna Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eterna Therapeutics' net worth analysis. One common approach is to calculate Eterna Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eterna Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eterna Therapeutics' net worth. This approach calculates the present value of Eterna Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eterna Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eterna Therapeutics' net worth. This involves comparing Eterna Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eterna Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Eterna Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eterna Therapeutics' net worth research are outlined below:
| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has some characteristics of a very speculative penny stock | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from newswire.com: BTX Precision Announces Acquisition of Addison Precision Manufacturing |
Eterna Therapeutics Quarterly Good Will |
|
Eterna Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eterna Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eterna Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Eterna Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eterna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eterna Therapeutics backward and forwards among themselves. Eterna Therapeutics' institutional investor refers to the entity that pools money to purchase Eterna Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 5 K | A. Montag & Associates Inc | 2024-06-30 | 212 | Bank Of America Corp | 2024-09-30 | 123 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 50.0 | Activest Wealth Management | 2024-09-30 | 50.0 | Royal Bank Of Canada | 2024-06-30 | 22.0 | Group One Trading, Lp | 2024-09-30 | 19.0 | Citigroup Inc | 2024-09-30 | 15.0 | Jpmorgan Chase & Co | 2024-09-30 | 14.0 | Ci Private Wealth Llc | 2024-09-30 | 262.9 K | Cypress Point Wealth Management, Llc | 2024-09-30 | 94.4 K |
Follow Eterna Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.64 M.Market Cap |
|
Project Eterna Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (9.70) | (9.22) |
When accessing Eterna Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eterna Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eterna Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Eterna Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eterna Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Eterna Therapeutics' management manipulating its earnings.
Evaluate Eterna Therapeutics' management efficiency
Eterna Therapeutics has return on total asset (ROA) of (0.2942) % which means that it has lost $0.2942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5418) %, meaning that it created substantial loss on money invested by shareholders. Eterna Therapeutics' management efficiency ratios could be used to measure how well Eterna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 14, 2024, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 114 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.42 | 0.40 | |
| Tangible Book Value Per Share | 0.04 | 0.03 | |
| Enterprise Value Over EBITDA | (2.20) | (2.09) | |
| Price Book Value Ratio | 4.28 | 4.42 | |
| Enterprise Value Multiple | (2.20) | (2.09) | |
| Price Fair Value | 4.28 | 4.42 | |
| Enterprise Value | 149.7 M | 157.2 M |
Leadership effectiveness at Eterna Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 73.8685 | Revenue 162 K | Revenue Per Share 0.03 | Return On Equity (11.54) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eterna Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eterna Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eterna Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eterna Therapeutics time-series forecasting models is one of many Eterna Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eterna Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Eterna Therapeutics Earnings per Share Projection vs Actual
Eterna Therapeutics Corporate Management
| Andrew Jackson | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Susan McClatchey | VP Quality | Profile | |
| Sandra Gurrola | Principal Finance | Profile | |
| Megan Yung | Chief Officer | Profile | |
| Roger MD | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.